The global Non-small Cell Lung Cancer Drugs market was valued at US$ 31,614.8 million in 2023 and is projected to reach US$ 68,888.6 million by 2029, at a CAGR of 9.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Drugs. This report contains market size and forecasts of Non-small Cell Lung Cancer Drugs in global, including the following market information:
- Global Non-small Cell Lung Cancer Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2023 (%)
The strong drug pipeline and drug approvals are one of the critical factors that will trigger the non-small cell lung cancer drugs market growth during the forecast period. With the increase in the prevalence of lung cancer, the need for a strong pipeline of disease-modifying drugs is also increasing.
We surveyed the Non-small Cell Lung Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-small Cell Lung Cancer Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Type, 2023 (%)
- Biologics
- Small Molecule Targeted Therapy
- Chemotherapy
- Other
Global Non-small Cell Lung Cancer Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, by Application, 2023 (%)
- Lung Adenocarcinoma
- Squamous Cell Lung Carcinoma
- Large-cell Lung Carcinoma
Global Non-small Cell Lung Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-small Cell Lung Cancer Drugs Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Non-small Cell Lung Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Non-small Cell Lung Cancer Drugs revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-small Cell Lung Cancer Drugs, market overview.
Chapter 2: Global Non-small Cell Lung Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-small Cell Lung Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
